I. Background

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

When a CGA is issued, it is posted on the IGL&C website in the Grants Process section and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations.

II. Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Eligibility Criteria:</td>
<td>The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.</td>
</tr>
</tbody>
</table>


Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.
III. Requirements

<table>
<thead>
<tr>
<th>Date CGA Issued:</th>
<th>1st February 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area:</td>
<td>Biosimilars</td>
</tr>
</tbody>
</table>

**Specific Area of Interest for this CGA:**

Education leading to a clear understanding of the appropriate use of biosimilars and other emerging concerns is critical for European pharmacists and physicians in preparing for their appropriate use in clinical practice. The intent of this CGA is to support educational programs that seek to improve the knowledge and competences of Oncology Health Care Professionals in the use of oncology biosimilar MAb in the European countries listed in the “Geographic Scope” section of this document.

Proposals should address one or more of the following areas of learning need:

- The critical importance of analytics in biosimilar development
- Extrapolation of indications based on the evaluation of the totality of evidence and mechanism of action rationale.
- Pharmacoeconomics
  - The importance of biosimilars in ensuring longterm sustainable healthcare
  - Please note that performing pharmacoeconomic analysis is out of scope for this grant.
- Potential of biosimilars to enable optimal combination therapy.
- Potential of biosimilars to enable “headroom” in order to afford novel treatments, equipment or other resources such as clinical staff.
- Issues surrounding clinician, nurse and patient confidence relating to the use of Biosimilars and strategies to mitigate them.
- Practice recommendations to ensure optimal patient information and consultation during biosimilar adoption / implementation.
- Topics related to role of a pharmacists in Biosimilar medicine optimization and pharmacovigilance.
- Education on how a sustainable biosimilar market may be achieved.

Projects will be required to provide enduring learning activities and practical resources.

Preference will further be given to applications from hospitals, universities, academic bodies and European medical societies.

Applications that have a broad geographic reach and the most accessible to a large population of Oncologists/ Pharmacists / Nurses and practical enduring materials will also be given greater preference.

### Expected Approximate Monetary Range of Grant Applications:

A maximum budget of $200,000 (Two hundred Thousand US Dollars) is available. This may be allocated to an individual project of high educational value or split between projects.

The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

### Key Dates:

- **CGA release date:** 1st February 2018
- **Grant application due date:** 2nd April 2018
  - Please note the deadline is midnight Eastern Time (New York, GMT -5).
- **Anticipated Grant Award Notification Date:** 14th May 2018
- **Grants will be distributed following execution of a fully signed Letter of Agreement**
- **Project start date on or after 1st July 2018**
- **Projects to be completed by October 2020**

### How to Submit:

- Please go to the specific [application log-in page](#) and sign in. First-time users should click “REGISTER NOW”.
- Select the following Educational Area: CGA- Biosimilars Oncology HCP Education Europe 2018
- Requirements for submission:
  - Complete all required sections of the online application and upload the completed CGA template (see Appendix).
  - If you encounter any technical difficulties with the grant management system, please click the “Need Support?” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted as the wrong application type and/or submitted after the due date will not be reviewed by the committee.

### Questions:

If you have questions regarding this CGA, please direct them in writing to Jo Harbron at (jo.harbron@pfizer.com), with the subject line “Biosimilars Treatment Europe 2018.”

### Mechanism by which Applicants will be Notified:

All applicants will be notified via email by the dates noted above.

Applicants may be asked for additional clarification or to make a summary presentation during the review period.

### IV. Terms and Conditions

Please take note every Call for Grant Applications (CGA) released by Pfizer Independent Grants for Learning & Change (IGLC) is governed by specific terms and conditions. These terms and conditions can be reviewed here: [http://www.pfizer.com/files/PfizerIGLC_CGA_TermsandConditions_2017Nov.pdf](http://www.pfizer.com/files/PfizerIGLC_CGA_TermsandConditions_2017Nov.pdf)
Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

A. Title
B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
C. Goal: Briefly state the overall goal of the project.
D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.
H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
K. Timeline
L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
M. References (outside the 15-page limit)
   • There is no designated format for references
N. Budget (See template available in application)
   • While estimating your budget please keep the following items in mind:
     • Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
     • Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
     • A separate Excel file should be uploaded. This does not count toward the page limit.
       • An example of the budget template can be found here: http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls
       • At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. There is a 15-page limit exclusive of references. If extensive, references may be included on 1-2 additional pages.